Quantcast

Latest Lymphoma Stories

2014-08-19 23:02:37

Lack of Access and Financial Burden May Contribute to Increased Mortality, CPIC Researchers Find Fremont, CA (PRWEB) August 19, 2014 Despite advances in treatment, lymphoma patients residing in low socioeconomic status (SES) neighborhoods experienced significantly worse survival than patients living in high SES neighborhoods, researchers at the Cancer Prevention Institute of California (CPIC) have reported. Those who live in the poorest communities have a 34 percent greater risk of dying...

2014-08-18 16:25:03

LONDON, Aug. 18, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Lymphoblastic Lymphoma-Pipeline Insights, 2014https://www.reportbuyer.com/product/2278641/-Lymphoblastic-Lymphoma-Pipeline-Insights-2014.htmlSUMMARYDelveInsight's," Lymphoblastic Lymphoma-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline...

2014-08-11 08:28:56

SAN DIEGO, Aug. 11, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the U.S. FDA has granted Orphan Drug Designation to mocetinostat, a spectrum selective HDAC inhibitor, for diffuse large B-cell lymphoma (DLBCL). In June, mocetinostat was granted Orphan Drug Designation as a treatment for myelodysplastic syndrome (MDS). Orphan drug designation is also being sought for bladder cancer patients with specific genetic alterations. Mocetinostat is being...

2014-08-06 16:28:52

Participants to Produce Strategic Roadmap for Accelerating Lymphoma Treatment Advances WASHINGTON, Aug. 6, 2014 /PRNewswire-USNewswire/ -- The American Society of Hematology (ASH), the world's largest professional organization dedicated to the causes and treatments of blood disorders, will hold its first ASH Meeting on Lymphoma Biology, a meeting focused on furthering the treatment of lymphoma, August 10-13 in Colorado Springs, Colorado. More than 350 lymphoma experts from around the...

2014-07-31 16:28:44

- IMBRUVICA Net Product Revenue Increased to $109.5 million for the Second Quarter of 2014 - SUNNYVALE, Calif., July 31, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter ended June 30, 2014. Financial Results for the Six Months and Quarter Ended June 30, 2014 Revenue Total revenue for the quarter ended June 30, 2014 increased to $113.0 million from $54.7 million for the quarter ended June 30,...

2014-07-29 12:35:55

The "Light The Night" Campaign has raised more than $2 million over 7 years SAN BERNARDINO, Calif., July 29, 2014 /PRNewswire/ -- Stater Bros. Charities and The Leukemia & Lymphoma Society (LLS) concluded another successful "Light The Night" fundraising campaign in support of LLS' mission to find cures and ensure access to treatments for blood cancer patients. These funds will also help LLS invest in research to advances cures for blood cancers....

2014-07-28 16:26:36

LONDON, July 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018https://www.reportbuyer.com/product/2225690/Global-Non-Hodgkin-Lymphoma-Therapeutics-Market-2014-2018.htmlAbout Non-Hodgkin Lymphoma (NHL) and its Diagnostic ProceduresNon-Hodgkin lymphoma (NHL) is a condition of the human body leading to the production of abnormal lymphocytes. In normal circumstances, the lymphocytes grow and die....

2014-07-25 08:26:13

SUNNYVALE, Calif., July 25, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA(®) (ibrutinib) in the European Union. IMBRUVICA is being jointly developed and commercialized in the United States by Pharmacyclics and Janssen Biotech, Inc. In Europe, once approved,...

2014-07-23 16:28:25

WHITE PLAINS, N.Y., July 23, 2014 /PRNewswire-USNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of idelalisib to treat patients with relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) is a significant advance for patients with these blood cancers. Idelalisib, which goes by the trade name Zydelig®, is a first-in-class inhibitor of PI3K delta, a protein that is highly expressed in many B-cell malignancies...

2014-07-21 04:21:39

SEATTLE, July 21, 2014 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) announced today that it has received approval from the Israeli Ministry of Health (MOH) for PIXUVRI(®) (pixantrone). PIXUVRI in Israel is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL) who have received not more than three previous courses of treatment. The benefit of pixantrone treatment has...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related